Company description

Biointron is an antibody-focused contract research organisation founded in 2012 and headquartered in Shanghai, China. The company provides high-throughput antibody discovery, optimisation and expression services to support drug discovery and early development programmes for biotech and pharmaceutical clients worldwide.

The company has established itself as a leading provider in the antibody expression space, offering rapid, scalable solutions that can deliver purified antibodies from gene sequence in as little as two weeks. Biointron has delivered tens of thousands of recombinant antibodies and supports more than 2,500–3,000 global customers, including major biopharmaceutical companies.

Biointron operates as a one-stop partner for antibody development, combining computational, molecular biology and laboratory capabilities to accelerate therapeutic discovery. Its services span antibody discovery, engineering and production, enabling clients to streamline workflows and reduce development timelines.

The company works with a wide range of organisations, including pharmaceutical companies, biotechnology firms and research institutions, supporting projects from early discovery through preclinical development. It emphasises rapid turnaround times, high-throughput capabilities and customised solutions tailored to client needs.

Key products and services

Antibody discovery services

• Single B-cell antibody screening
• VHH (nanobody) discovery
• Fully human antibody discovery platforms
• Hybridoma sequencing and antibody identification

Antibody engineering and optimisation

• Antibody humanisation
• Affinity maturation and optimisation
• Bispecific antibody development
• Antibody characterisation and validation

Recombinant antibody and protein expression

• High-throughput recombinant antibody production
• Rapid expression from gene sequence to purified antibody
• Protein expression and purification services

Molecular biology and related services

• DNA and RNA services
• Gene synthesis and vector construction
• Cell line development and transfection support

Integrated CRO solutions

• End-to-end antibody development workflows
• Customised project design and execution
• Support for drug discovery and early development programmes

By combining high-throughput antibody discovery, engineering expertise and rapid production capabilities, Biointron enables pharmaceutical and biotechnology companies to accelerate therapeutic development and reduce time to clinic. Its integrated CRO model, global client base and focus on efficiency position the company as a specialist partner in antibody-based drug discovery and biologics development.